IEX — IDEX Corporation

As of 2026-09-13, the primary sentiment remains constructive after Q2 2026 net sales rose 6% to $920.6M, adjusted diluted EPS hit a record $2.32, organic orders jumped 28% overall with Health & Science Technologies orders up 47%, and management raised FY26 organic growth guidance to 5-6% and adjusted EPS to $8.70-$8.85. The 1-month -6.8% pullback and RSI of 42.9 show near-term profit-taking, but the 6-month +19.2% return and price still above the 200-day SMA keep the bigger-picture tone positive.

Revenue has inflected higher: from roughly $789-$807M per quarter in 2023-24 to $878.7M in Q3 2025, $899.1M in Q4 2025, $886.9M in Q1 2026, and a record $920.6M in Q2 2026. YoY growth was 1.7% in Q1 2025, 7.2% in Q2 2025, 10.1% in Q3 2025, 4.2% in Q4 2025, 8.9% in Q1 2026, and 6.4% in Q2 2026—positive but uneven, not a straight acceleration. Operating margin has been range-bound: 19.7% in Q1 2025, 22.0% in Q2 2025, 21.1% in Q3 2025, 20.7% in Q4 2025, 19.4% in Q1 2026, and 21.7% in Q2 2026, so Q2 shows sequential recovery rather than a structural breakout. Diluted EPS moved from $1.26 in Q1 2025 to $1.93 in Q2 2026 (GAAP), with adjusted EPS at a record $2.32; note that Q3 2023's $2.75 EPS is an outlier versus the $1.4-$2.0 range, so the clean trend is better read from 2024 onward. The strongest forward signal is the 28% organic order growth, which suggests the recent inflection can continue if HST demand converts to revenue.

Expensive on trailing, more reasonable on forward. As of 2026-09-13, TTM P/E is 32.2x versus a 5-year average of 31.2x, P/S is 4.61x versus a 5-year average of 5.13x, and PEG is 2.55. But forward P/E on the $8.83 EPS estimate is about 25.4x, which is below the 5-year average multiple if FY26 guidance around $8.70-$8.85 is hit. The stock is not cheap in absolute terms, but the premium is digestible only if 5-6% organic growth and double-digit adjusted EPS growth materialize.

The market is pricing in the Q2 2026 beat and raised guidance but still applies a discount to IDEX's 5-year average P/E—forward P/E is 25.4x versus the 5-year average of 31.2x. That means upside likely requires order conversion and margin expansion to show up in reported EPS; a Q3 miss or slower HST orders would make the premium look stretched. Conversely, if 2026 EPS lands at the guided $8.70-$8.85 and 2027 estimates move higher, the stock could re-rate toward the high-$240s/low-$250s without needing multiple expansion.

As of 2026-09-13, RSI is 42.9, price is 2.5% below the 20-day SMA and 1.9% below the 50-day SMA, but 8.3% above the 200-day SMA. This is a pullback within a longer uptrend, not an oversold washout—RSI is neutral-to-soft, not below 30. Entry-timing implication: waiting for a reclaim of the 50-day SMA or a deeper RSI flush would offer better risk/reward than chasing the current bounce.

• Semiconductor, data-center, and space/defense capex cycles are key demand drivers; HST orders up 47% in Q2 2026 show cyclical upside but also expose IDEX to a sharp capex slowdown.
• Tariff policy remains a swing factor: Q2 2026 cash flow included a $21.1M one-time IEEPA tariff refund, and future tariff changes could affect costs or demand.
• Industrial sector rotation and interest-rate expectations influence the multiple on high-quality machinery names; a higher-for-longer rate backdrop pressures premium P/E stocks.
• Segment divergence: HST is booming while other industrial pockets are softer, so mix and 80/20 productivity execution matter for consolidated margins.
• M&A integration and capital deployment (e.g., Mott) affect growth and returns; IDEX has a strong balance sheet to fund bolt-ons but integration risk is real.

• Q3 2026 earnings in late October 2026—confirms whether Q2's 28% organic order growth converts to revenue and whether adjusted EBITDA margin holds near 28.1%.
• Full-year 2026 guidance of 5-6% organic growth and $8.70-$8.85 adjusted EPS; any raise or cut will drive the stock.
• Semiconductor, data-center, and defense order momentum, especially in HST, plus new product/capacity investments.
• Continued buybacks and dividends—$131M returned in Q2 2026—plus the credit facility maturity extension to 2031.

• Premium valuation: 32.2x TTM P/E and 19.8x EV/EBITDA leave little room for execution misses; a slowdown in HST orders could compress the multiple.
• Cyclical demand in semiconductors, data centers, and defense/space could reverse; Q2's 47% HST order growth may not be repeatable.
• Segment divergence and softer non-HST industrial activity could offset HST strength and pressure consolidated margins.
• Tariff, supply-chain, and FX volatility, plus one-time items like the $21.1M IEEPA refund, could distort cash flow and reported results.
• M&A integration and capital allocation risk if recent acquisitions such as Mott underperform.

IDEX is a high-quality industrial compounder with a strong balance sheet, resilient margins, and an order book that just inflected sharply, but the stock already trades at a premium and near the high end of its 52-week range. As of 2026-09-13, the pullback below the 20/50-day SMAs offers a more reasonable entry than a month ago, but the risk/reward is balanced rather than screaming cheap; I would want Q3 confirmation of order conversion before treating the recent beat as a durable re-rating.

I apply a 28.5x forward P/E to the FY2026 EPS estimate of $8.832. That multiple is a modest discount to IDEX's 5-year average P/E of 31.23x—justified by cyclical semiconductor/defense exposure and the current premium multiple—but a premium to the current 25.4x forward P/E to reflect raised guidance and 28% organic order growth. 8.832 × 28.5 = $251.71.